Latest Trials Latest NewsFAQ

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Phase 3

Recruiting

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Remibrutinib
Drug: Teriflunomide

First Posted Date: 2021-12-07

Last Posted Date: 2024-08-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 800

Registration Number: NCT05147220

Locations: 🇺🇸
Homestead Assoc In Research Inc, Homestead, Florida, United States
🇺🇸
NYU Langone Health Research, Brooklyn, New York, United States
🇺🇸
AZ Integrated Neuro and Spine Integrated MS Center, Phoenix, Arizona, United States

and more 64 locations

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Completed

Conditions: Age-related Macular Degeneration (AMD)

Interventions: Other: Aflibercept
Other: Bevacizumab
Other: Ranibizumab

First Posted Date: 2021-12-07

Last Posted Date: 2021-12-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 369600

Registration Number: NCT05146687

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Phase 1

Recruiting

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: [177Lu]Lu-DOTA-TATE
Drug: Atezolizumab
Drug: [68Ga]Ga-DOTA-TATE
Other: Carboplatin
Other: Etoposide

First Posted Date: 2021-12-02

Last Posted Date: 2024-10-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT05142696

Locations: 🇺🇸
Georgetown University Lombardi Cancer Center, Washington, District of Columbia, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇬🇧
Novartis Investigative Site, Guildford, Surrey, United Kingdom

and more 1 locations

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Ribiciclib
Drug: Abemaciclib
Drug: Palbociclib

First Posted Date: 2021-12-02

Last Posted Date: 2021-12-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 4650

Registration Number: NCT05141240

Locations: 🇺🇸
Novartis Investigational site, East Hanover, New Jersey, United States

Impact of Fingolimod Adherence on Outcomes

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Fingolimod

First Posted Date: 2021-12-02

Last Posted Date: 2021-12-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 694

Registration Number: NCT05141669

Locations: 🇺🇸
Novartis Investigational Site, East Hanover, New Jersey, United States

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension

Phase 2

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: LTP001
Drug: Placebo

First Posted Date: 2021-11-26

Last Posted Date: 2024-08-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 47

Registration Number: NCT05135000

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom
🇺🇸
Pulmonary Associates PA, Mesa, Arizona, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: JDQ443
Drug: docetaxel

First Posted Date: 2021-11-24

Last Posted Date: 2024-11-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 95

Registration Number: NCT05132075

Locations: 🇺🇸
Valley Medical Center Research Valley Professional Center Bld, Renton, Washington, United States
🇺🇸
Valley Medical Center Research, Renton, Washington, United States
🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Phase 3

Recruiting

Conditions: Lupus Nephritis

Interventions: Drug: ianalumab s.c. q4w
Drug: placebo s.c.
Drug: ianalumab s.c. q12w

First Posted Date: 2021-11-19

Last Posted Date: 2024-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 420

Registration Number: NCT05126277

Locations: 🇺🇸
University Of Alabama, Birmingham, Alabama, United States
🇺🇸
Wallace Rheumatic Study Center, Los Angeles, California, United States
🇺🇸
University of California LA, Los Angeles, California, United States

and more 31 locations

Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.

Phase 2

Active, not recruiting

Conditions: Sjogren Syndrome

Interventions: Biological: Ianalumab

First Posted Date: 2021-11-18

Last Posted Date: 2024-08-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 21

Registration Number: NCT05124925

Locations: 🇫🇷
Novartis Investigative Site, Brest, France

An Observational Prospective Study to Characterize Patients Initiating Enerzair® Breezhaler®, With or Without Sensor, as a Maintenance Treatment for Asthma

Withdrawn

Conditions: Asthma

Interventions: Other: IND/GLY/MF

First Posted Date: 2021-11-16

Last Posted Date: 2022-04-04

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05120986

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy